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Abstract
Introduction: The distinction of papillary thyroid carcinomas from benign thyroid lesions has important implication for clinical man-
agement. Classification based on histopathological features can be supported by molecular biomarkers, including lipidomic signatures, 
identified with the use of high-throughput mass spectrometry techniques. Formalin fixation is a standard procedure for stabilization 
and preservation of tissue samples, therefore this type of samples constitute highly valuable source of clinical material for retrospective 
molecular studies. In this study we used mass spectrometry imaging to detect lipids discriminating papillary cancer from not cancerous 
thyroid directly in formalin-fixed tissue sections.
Material and methods: For this purpose imaging and profiling of lipids present in non-malignant and cancerous thyroid tissue specimens 
were conducted. High resolution MALDI-Q-Ion Mobility-TOF-MS technique was used for lipidomic analysis of formalin fixed thyroid 
tissue samples. Lipids were identified by the comparison of the exact molecular masses and fragmentation pathways of the protonated 
molecule ions, recorded during the MS/MS experiments, with LIPID MAPS database.
Results: Several phosphatidylcholines (32:0, 32:1, 34:1 and 36:3), sphingomyelins (34:1 and 36:1) and phosphatidic acids (36:2 and 36:3) 
were detected and their abundances were significantly higher in cancerous tissue compared to non-cancerous tissue. The same lipid 
species were detected in formalin-fixed as in fresh-frozen tissue, but [M + Na]+ ions were the most abundant in formalin fixed whereas 
[M + K]+ ions were predominant in fresh tissue. 
Conclusions: Our results prove the viability of MALDI-MSI for analysis of lipid distribution directly in formalin-fixed tissue, and the 
potential for their use in the classification of thyroid diseases. (Endokrynol Pol 2018; 69 (1): 2–8)
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Streszczenie
Wstęp: Rozróżnienie brodawkowatych raków tarczycy od łagodnych zmian tarczycy ma istotny wpływ na postepowanie kliniczne. 
Klasyfikacja w oparciu o cechy histopatologiczne może być wspomagana biomarkerami molekularnymi, w tym składnikami lipidowymi, 
zidentyfikowanymi przy użyciu wysokorozdzielczych technik spektrometrii masowej. Utrwalanie tkanki w formalinie jest standardową 
procedurą stabilizacji i konserwacji tkanek, które stanowią cenne źródło materiału klinicznego w retrospektywnych badaniach moleku-
larnych. W prezentowanych badaniach wykorzystano obrazowanie molekularne metodą MALDI w celu wykrycia składników lipidomu, 
obecnych w tkankach utrwalonych w formalinie, różnicujących raka brodawkowatego od tarczycy nienowotworowej.
Materiał i metody: W tym celu przeprowadzono obrazowanie i profilowanie lipidów obecnych w próbkach tkanek tarczycy zmienionej 
nowotworowo i nienowotworowej. Do analizy lipidomicznej tkanek tarczycy utrwalonych w formalinie zastosowano wysokorozdzielczą 
technikę MALDI-Q-Ion Mobility-TOF-MS. Składniki lipidowe zostały zidentyfikowane przez porównanie uzyskanych dokładnych mas czą-
steczkowych i szlaków fragmentacji jonów protonowanych, zarejestrowanych podczas eksperymentów MS/MS, z bazą danych LIPID MAPS.
Wyniki: W oparciu o przeprowadzone analizy wykryto lipidy należące do klas fosfatydylocholin (32:0, 32:1, 34:1 i 36:3), sfingomielin (34:1 
i 36:1) i kwasów fosfatydowych (36:2 i 36:3), a ich ilość była znacząco wyższa w tkance nowotworowej w porównaniu z tarczycą nieno-
wotworową. Te same składniki lipidowe wykryto w preparatach utrwalonych w formalinie, jak i w tkance świeżo mrożonej, przy czym 
jony [M + Na]+ obecne były w przewadze w tkance utrwalonej w formalinie, podczas gdy w świeżej tkance przeważały jony [M + K]+.
Wnioski: Prezentowane wyniki potwierdzają możliwości wykorzystania techniki MALDI-MSI w analizie dystrybucji lipidów bezpo-
średnio w tkankach stabilizowanych formaliną oraz dają nadzieję na potencjalne wykorzystanie ich w klasyfikacji chorób tarczycy. 
(Endokrynol Pol 2018; 69 (1): 2–8)
Słowa kluczowe: obrazowanie metodami spektrometrii masowej, brodawkowaty rak tarczycy, lipidomika kliniczna,  
próbki tkanek stabilizowane formaliną
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Introduction 
Papillary thyroid carcinomas (PTC) are the most com-
mon thyroid cancers and constitute more than 70% of 
all thyroid malignancies [1]. Classification of thyroid 
lesion is critical for prognosis and treatment selection, 
hence the distinction of PTC from other malignant and 
benign thyroid lesions has important implications for 
clinical management. Diagnosis of PTC is based on its 
histological pattern involving specific papillary archi-
tecture, yet some papillary carcinomas show not the 
typical histological features [2, 3]. Moreover, diagnosis 
of thyroid cancers is initially based on the fine needle 
aspiration cytology of thyroid nodules [4]. However, 
morphology-based methods have several limitations 
restricting correct classification of cancer subtypes [5, 6]. 
Hence, classification of different thyroid cancer sub-
types could be facilitated if histological/cytological pat-
terns were supported by molecular biomarkers.
Lipids are among classes of biomolecules with a high 
potential value in cancer diagnostics [7]. Phospholipids, 
which are the major constituents of cell membranes, 
play an important role in signal transduction, inflam-
mation, cell proliferation and differentiation [8–10], 
and influence key aspects of cancer phenotype [11, 12]. 
A few papers have reported differences in the lipid 
profiles of thyroid neoplasms [13–16], hence this class 
of compounds could be potentially implemented in 
classification of thyroid lesions. Mass spectrometry 
imaging (MSI) is a newly developed technique allowing 
for determination of spatial distribution of metabolites 
and lipids within the tissue sections [17–20]. An impor-
tant advantage of molecular profiling by MSI lays on its 
ability to use spectra exported from specific tissue areas 
defined by a pathologist based on their morphological 
features, which might be called a “virtual microdissec-
tion”. Formalin fixation (FF) is a standard procedure for 
stabilization and preservation of tissue specimens for 
clinical purposes. However, fixation process impairs the 
ability to analyse certain classes of biomolecules [21, 22]. 
Recently, we demonstrated that tissues fixed with 
formalin and processed without paraffin embedding 
were suitable for imaging of lipids by MALDI (matrix- 
-assisted laser-desorption ionization)-MSI [23]. In the 
present study this approach was used for profiling of 
lipids in FF tissue to detect species discriminating PTC 
from non-cancerous thyroid. 
Material and methods
Clinical material
Tissue samples were collected from 3 Caucasian patients 
with PTC treated in Maria Sklodowska-Curie Institute 
(Gliwice, Poland). Samples were obtained from a cancer 
and adjacent non-cancerous thyroid tissue immedi-
ately after tumour resection. Detailed information on 
clinical samples is given in the Supplementary Table sI. 
Immediately after resection tissue specimens were fixed 
in neutral buffered formalin (4% formaldehyde in phos-
phate buffer, pH 7.0) for 24 hours at room temperature, 
and stored in –80°C until analysed. Some of the tissue 
samples were also frozen in liquid nitrogen. 
Tissue sample preparation and matrix deposition
Ten µm thick tissue sections were prepared using 
a cryostat, and then serial sections were mounted 
onto indium tin oxide (ITO) either coated glass slides 
(Bruker, Germany) for MSI or standard glass slides for 
hematoxylin and eosin (H&E) staining. Each tissue 
section for MSI was washed twice with distilled water 
(2 × 30 seconds), and then covered with a-cyano-4-
hydroxycinnamic acid (CHCA) matrix solution (0.5% 
a-cyano-4-hydroxycinnamic acid in 70% methanol and 
0.2% trifluoroacetic acid) in a series of 4 layers (5 µL/min) 
using SunCollect Instrument (SunChrom, Germany).
Mass spectrometry analysis
Mass spectrometry imaging was performed using 
a HDMS SYNAPT TM G2 system and Driftscope 2.1 
software (Waters, UK). Mass spectrometry (MS) and 
tandem mass spectrometry (MS/MS) data were acquired 
in positive ion sensitivity mode at a mass resolution of 
10 000 full width at half maximum (FWHM) with ion 
mobility separation enabled and over the mass range 
m/z 100 to 1200. Image acquisition was performed us-
ing raster imaging mode at 100 μm spatial resolution, 
Biomap 3.7.5.5 software (http://www.maldi-msi.org/) 
was used for image generation. The MS/MS spectra 
were acquired manually moving the laser position and 
adjusting the collision energy to achieve good signal 
to noise for product ions across the full m/z range of 
the spectrum. Collision energies were adjusted from 
25 to 40 eV during acquisition and acquisition times 
were generally of the order of 5–10 s per spectrum. 
Lipids were identified by the comparison of the exact 
molecular masses and fragmentation pathways of the 
protonated molecule ions, recorded during the MS/
MS experiments, with LIPIDMAPS database (www.
lipidmaps.org) Positive identification of molecular ions 
was assumed if a unique match with error below 3 ppm 
was found.
Statistical analysis
Mass spectra were pre-processed and spectral com-
ponents were detected using the Gaussian Mixture 
Model as described in details elsewhere [24]. Due to 
significant deviations from normal distribution the non-
parametric Kruskal-Wallis ANOVA was used to check 
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equality of location statistics among populations of 
spectra (the Benjamini-Hochberg correction for multi-
ple testing was applied). The post hoc multiple pairwise 
comparisons were done by Dunn’s test. The results of 
statistical testing were supported by estimation of the 
pairwise Wilcox-Tian’s effect size; the effects above 0.8 
with appropriate pairwise comparison p-value less than 
0.05 were considered significantly large. 
Results
Cancer and non-cancerous regions of interest (ROIs) 
were defined by a pathologist in the tissue specimen 
from each patient and 100 spectra were imported from 
each ROI (average mass spectra from each ROI are pre-
sented in Fig. 1); 476 components representing molecu-
lar species with their isotopic envelopes were detected 
in the 700–900 Da mass range. For each pair of ROIs the 
statistical significance of differences in abundance of 
each spectral component was estimated (numbers of 
differentiating components are listed in Table I). The 
average number of differentiating components between 
paired cancer and noncancerous ROIs was 229. On the 
other hand, average number of differentiating compo-
nents among all cancer ROIs was 232, while average 
number of differentiated components among all non-
cancerous ROIs was 281. This might suggest a higher 
degree of similarity among PTC from different patients 
than among non-cancerous thyroid regions from dif-
ferent patients. However, this unexpected observation 
could be explained when considering that “non-can-
cerous” regions include one “normal” thyroid tissue 
(Patient_2) and two non-cancerous thyroid diseases: 
nodular goiter (Patient_1) and lymphocytic thyroiditis 
(Patient_3). Nevertheless, when the overlap of cancer-
upregulated or downregulated components between 
three different patients were analysed 33 commonly 
upregulated and 23 commonly downregulated com-
ponents were detected. Furthermore, when combined 
spectra from all cancer ROIs and all non-cancerous ROIs 
were compared, 34 cancer-upregulated and 27 cancer-
downregulated components were detected. Hence, we 
concluded that spectral components corresponding 
to lipid species could be detected that generally dis-
criminate papillary thyroid cancer from non-cancerous 
thyroid tissue, not only normal healthy thyroid but also 
not neoplastic lesions.
Annotation of abundant components of registered 
spectra (i.e. spectral components with abundances high-
er than median) the LIPID MAPS database allowed hy-
pothetical identification of 48 molecular species, which 
corresponded to [M + H]+, [M + Na]+ and [M + K]+ 
ions of 22 lipids, including 12 phosphatidylcholines 
(PCs), 6 phosphatidic acids (PAs) and 4 sphingomyelins 
(SMs). In general, we observed the same molecular ions 
corresponding to lipid species in formalin-fixed and 
fresh-frozen thyroid tissue, yet sodium adducts were 
the most abundant in the former material whereas po-
tassium adducts predominated in the latter type of ma-
terial. Moreover, the abundance of registered ions was 
higher in fresh-frozen tissue (Supplementary Fig. s1). 
Hence, to verify the identity of detected lipids selected 
components were analysed by in tissue MS/MS in 
corresponding fresh-frozen cancerous tissue (Sup-
plementary Fig. s2, Tab. sII). This analysis allowed the 
validation of the identity of 26 molecular ions. 
Abundances of all 22 identified lipid species detected 
in thyroid tissue were compared pairwise in cancer and 
non-cancerous ROI for each patient separately (Table II). 
There were 13 lipid species (with 25 molecular ions) that 
showed cancer-upregulation in all 3 patients. Further-
more, increased abundance of 8 lipids in cancerous tis-
sue was highly statistically significant, which included: 
phosphatidylcholines PC(32:0), PC(32:1), PC(34:1) and 
PC(36:3), phosphatidic acids PA(36:2) and PA(36:3), 
and sphingomyelins SM(34:1) and SM(36:1) (Fig. 2). 
This is noteworthy, in that several lipid species were 
not upregulated in cancerous thyroid when compared 
to colloid nodular goiter (Patient_1), which represents 
a benign thyroid neoplasm. Hence, these lipids did 
Table I. Numbers of spectral components differentiating compared ROIs
Tabela I. Liczba różnicujących składników widm w oparciu o porównanie obszarów ROI
CTR-1 CTR-2 CTR-3 CAN-1 CAN-2 CAN-3
CTR-1 x 257 286 254 219 209
CTR-2 x 299 183 205 272
CTR-3 x 275 299 227
CAN-1 x 198 249
CAN-2 x 249
CAN-3 x
Presented are numbers of spectral components that showed significantly different abundances (corrected p-value < 0.05 and effect size > 0.8) between all ROIs 
compared pairwise; CTR — non-cancerous (control); CAN — cancer; 1,2,3 — patients numbers
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Figure 1. Averaged mass spectra from cancerous and non-cancerous areas of thyroid tissue
Rycina 1. Uśrednione widma masowe z obszarów nowotworowych i nienowotworowych tkanek tarczycy
not discriminate universally, PTC from non-cancerous 
thyroid. Lipids that were relatively downregulated in 
normal and inflammatory thyroid yet upregulated in 
nodular goiter included PC(36:2), PC(38:3), PC(38:4), 
PA(38:3), PA(38:5), SM(40:1) and SM(42:2).
A few papers have previously reported specific dif-
ferences in lipid profiles between thyroid malignancies 
and non-cancerous thyroid, however in these studies 
chemically fixed tissue was not employed. Increased 
abundances of PC(34:1), PC(34:2) and SM(34:1) were 
observed in PTC when compared to healthy thyroid 
[17]. Moreover, PC(34:1), PA(36:3) and SM(34:1) could 
discriminate between thyroid cancers (PTC and FTC), 
benign thyroid neoplasms and normal thyroid [19]. 
Furthermore, increased levels of lipids with monoun-
saturated acyl chains relative to polyunsaturated lipid 
species were found to be characteristic of the thyroid 
cancer microenvironment [20]. 
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Table II. Identified lipids that differentiate PTC from non-cancerous thyroid tissue
Tabela II. Zidentyfikowane lipidy, które różnicują tkanki PTC od nienowotworowych tkanek tarczycy
Compound ion registered m/z [Da] Pt_1 Pt_2 Pt_3
Cancer/Non-
cancerous ratio
Corrected 
p-value Effect size
PC (32:0)
[M + H] + 734.57 Up Up Up 1.94 <0.001 0.62
[M + Na] + 756.55 Up Up Up 1.70 <0.001 0.69
[M + K] + 772.53 Up Up Up 1.05 0.004 0.18
PC (32:1)
[M + Na] + 754.54 Up Up Up 1.45 <0.001 0.52
[M + K] + 770.51 Up Up Up 1.21 <0.001 0.57
PC (34:1) 
[M + H] + 760.58 Down Up Up 1.22 <0.001 0.28
[M + Na] + 782.57 Up Up Up 1.31 <0.001 0.77
[M + K] + 798.54 Up Up Up 1.36 <0.001 0.51
PC (34:2) 
[M + H] + 758.57 Down Up Up 1.09 0.001 0.09
[M + Na] + 780.55 Up Up Up 1.03 0.012 0.17
[M + K] + 796.53 Up Up Up 1.29 <0.001 0.38
PC (36:1)
[M + H] + 788.62 Down Up Up 0.84 0.001 0.26
[M + Na] + 810.59 Down Up Up 3.03 <0.001 0.07
[M + K] + 826.58 Up Up Up 0.98 0.437 0.03
PC (36:2)
[M + H] + 786.60 Down Up Up 2.10 0.002 0.02
[M + Na] + 808.58 Down Up Up 0.78 <0.001 0.32
[M + K] + 824.56 Down Up Up 0.99 0.482 0.16
PC (36:3)
[M + H] + 784.58 Up Up Up 1.18 <0.001 0.23
[M + Na] + 806.57 Down Up Up 0.82 0.344 0.08
[M + K] + 822.54 Up Up Up 1.18 <0.001 0.50
PC (36:4)
[M + Na] + 804.55 Up Up Up 0.98 0.084 0.22
[M + K] + 820.52 Up Up Up 1.20 <0.001 0.44
PC (38:3) [M + Na] + 834.59 Down Up Up 0.76 0.376 0.01
PC (38:4)
[M + Na] + 832.58 Down Up Up 0.73 0.004 0.16
[M + K] + 848.56 Down Up Up 0.98 0.441 0.03
PC (38:5)
[M + Na] + 830.57 Down Up Up 0.75 0.454 0.01
[M + K] + 846.54 Up Up Up 0.92 <0.001 0.39
PC (38:6) [M + K] + 844.52 Up Up Up 0.99 0.131 0.11
PA (36:2) 
[M + Na] + 723.49 Up Up Up 1.14 <0.001 0.29
[M + K] + 739.47 Up Up Up 1.60 <0.001 0.91
PA (36:3)
[M + Na] + 721.48 Down Up Up 2.69 0.022 0.15
[M + K] + 737.45 Up Up Up 1.48 <0.001 0.72
PA (38:3) [M + Na] + 749.51 Down Up Up 0.74 <0.001 0.56
PA (38:4)
[M + Na] + 747.49 Up Up Up 1.04 0.231 0.01
[M + K] + 763.47 Up Up Up 0.94 <0.001 0.27
PA (38:5)
[M + Na] + 745.48 Down Up Up 0.93 0.017 0.14
[M + K] + 761.45 Down Up Up 1.14 0.001 0.18
PA (40:5)
[M + H] + 751.53 Down Up Up 0.77 <0.001 0.27
[M + Na] + 773.51 Down Up Up 0.84 <0.001 0.37
[M + K] + 789.48 Up Up Up 0.98 0.011 0.16
SM (40:1) [M + Na] + 809.65 Down Up Up 0.71 <0.001 0.23
SM (42:2)
[M + Na] + 835.67 Down Up Up 0.90 0.001 0.24
[M + K] + 851.64 Down Up Up 0.94 0.010 0.16
SM (34:1)
[M + H] + 703.57 Up Up Up 1.41 <0.001 0.50
[M + Na] + 725.58 Up Up Up 1.78 <0.001 1.01
[M + K] + 741.53 Up Up Up 1.58 <0.001 0.56
SM (36:1)
[M + Na] + 753.59 Down Up Up 1.27 <0.001 0.54
[M + K] + 769.56 Up Up Up 0.99 0.837 0.11
Up and Down refers to relative upregulation and downregulation of compound in cancer ROI compare to matched non-cancerous ROI in subsequent patients (Pt_1, 
Pt_2, Pt_3); Cancer/Non-cancerous ratio (and corresponding statistical indices) refers to combined spectra from all Cancer ROIs and Non-cancerous ROIs
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Figure 2. Abundances of selected lipids in cancer 
and non-cancerous ROIs from three patients with 
PTC. Boxplots show minimum, lower quartile, 
median, upper quartile and maximum values
Rycina 2. Ilości wybranych lipidów z nowo- 
tworowych i nienowotworowych obszarów ROI 
pobranych od trzech pacjentów z PTC. Wykresy 
pokazują wartości minimalne, niższy kwartyl, 
mediany, górny kwartyl i wartości maksymalne PA — phosphatidic acids; PC — phosphatidylcholine; SM — sphingomyelin
Conclusions
Here we performed profiling of lipid species in 
formalin-fixed thyroid tissue, proving that this type of 
clinical material is compatible with mass spectrometry 
(MS)-based metabolomics/lipidomics studies. Several 
phosphatidylcholine, sphingomyelin and phosphatidic 
acid species were identified and quantified in analysed 
tissues. It was found that eight phospholipids, includ-
ing PC(32:0), PC(32:1), PC(34:1), PC(36:3), PA(36:2), 
PA(36:3), SM(34:1) and SM(36:1), were upregulated 
in PTC and could be used to discriminate this ma-
lignancy from non-malignant thyroid tissue, either 
“normal” or benign neoplasm. This observation vali-
dated and further extended previous reports [17, 19]. 
Furthermore, several other lipid species that could 
putatively discriminate normal thyroid (either healthy 
or inflammatory) from benign thyroid neoplasms were 
detected. Hence, we confirmed that lipid profiling by 
MALDI-MSI could be potentially used for classification 
and differentiating diagnosis of thyroid diseases based 
on clinically relevant material (formalin-fixed tissue). 
An advantage of this MSI approach in comparison to 
other MS-based analytical techniques lays in its unique 
ability to “extract” molecular information from small 
defined tissue regions. This is particularly helpful in 
cases where several distinct diseases co-exist within 
the same tissue specimen.
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